Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset

This publication has 37 references indexed in Scilit:

• The clinical dilemma of high-risk stage II colon cancer: are we truly prepared to withdraw oxaliplatin?
  ESMO Open, 2024
• Minimal residual disease as a target for liquid biopsy in patients with solid tumours
  Nature Reviews Clinical Oncology, 2024
• Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for initially unresectable locally advanced colon cancer: short-term outcomes of an open-label, single-centre, randomised, controlled, phase 3 trial
  eClinicalMedicine, 2024
• Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer
  New England Journal of Medicine, 2024
• Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer
  Nature Medicine, 2023
• Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
  New England Journal of Medicine, 2022
• A new prognostic and predictive tool for shared decision making in stage III colon cancer
  European Journal of Cancer, 2020
• Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
  Annals of Oncology, 2020
• Survival impact of adjuvant chemotherapy in patients with stage IIA colon cancer: Analysis of the National Cancer Database
  International Journal of Cancer, 2020
• Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis
  European Journal of Cancer, 2010